Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Nursing home lockdowns: Life-Saver or silent threat?

NCT ID NCT04740658

Knowledge-focused Sponsor: University Hospital, Toulouse Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study examined whether strict COVID-19 rules in nursing homes (like banning visitors and confining residents) saved lives or caused harm. Researchers tracked over 12,000 residents for one year, comparing death rates in homes that followed guidelines closely versus those that did not. The goal was to understand if these measures reduced COVID deaths but increased deaths from other causes due to isolation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

12,166 people

The number who actually took part.

Started

Jul 2021

Finished

Mar 2022

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

NH volunteers located in different regions more or less affected by the epidemic and NH coordinating physician/directors of NHs via the SFGG website, directors of large private groups (Korian, Orpea, Edenis, DOMUS-vi ..) or public groups (APHP), regional (FMC Gériatres 31) and national (FFAMCO) NH coordinating physician associations (FFAMCO, MCOOR), the referents geriatricians of large cities that have been particularly exposed to the epidemic (Mulhouse, Strasbourg, Paris) or particularly least exposed (Bordeaux, Brest).

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Within each NH, all NH residents living in the NH the 1st of January 2020 will be included. Exclusion Criteria: * NHs or Long Term Care Facilities (LTCFs) that refuse to participate. * NHs that are not voluntary or not located in the regions and NHs that do not have a coordinating doctor . * Within each NH, all NH residents not living in the NH or LTCFs the 1st of January 2020 will be not be included.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID19 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

COVID-19

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COVID19

Contacts and locations

Locations

  • University Hospital Toulouse - Gérontopôle

    Toulouse, 31059, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.